Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 18:e177003.
doi: 10.1172/jci.insight.177003. Online ahead of print.

A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models

Paul R Stabach  1 , Dominique Sims  1 , Eduardo Gomez-Bañuelos  2 , Sandra Zehentmeier  3 , Kris Dammen-Brower  4 , Andrew Bernhisel  1 , Sophia E Kujawski  5 , Sam G Lopez  1 , Michelle Petri  2 , Daniel W Goldman  2 , Ethan R Lester  1 , Quan Le  1 , Tayyaba Ishaq  1 , Hana Kim  1 , Shivani Srivastava  1 , Deepika Kumar  1 , Joao P Pereira  3 , Kevin J Yarema  4 , Fotios Koumpouras  5 , Felipe Andrade  2 , Demetrios T Braddock  1
Affiliations
Free article

A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models

Paul R Stabach et al. JCI Insight. .
Free article

Abstract

A defining feature of systemic lupus erythematosus (SLE) is loss of tolerance to self-DNA, and DNASE1L3 deficiency, the main enzyme responsible for chromatin degradation in blood, is also associated with SLE. This association includes an ultra-rare pediatric population with DNASE1L3 deficiency who develop SLE, adult patients with loss of function variants of DNASE1L3 who are at a higher risk for SLE, and patients with sporadic SLE who have neutralizing autoantibodies to DNASE1L3. To mitigate the pathogenic effects of inherited and acquired DNASE1L3 deficiencies, we engineered a long-acting enzyme biologic with dual DNASE1/DNASE1L3 activity that is resistant to DNASE1 and DNASE1L3 inhibitors. Notably, we found that the biologic prevented the development of lupus in Dnase1-/-/Dnase1L3-/- double knockout mice and rescued animals from death in pristane-induced lupus. Finally, we confirmed that the human isoform of the enzyme biologic was not recognized by autoantibodies in SLE and efficiently degrades genomic and mitochondrial cell free DNA, as well as microparticle DNA, in SLE plasma. Our findings suggest that autoimmune diseases characterized by aberrant DNA accumulation, such as SLE, can be effectively treated with a replacement DNASE tailored to bypass pathogenic mechanisms, both genetic and acquired, that restrict DNASE1L3 activity.

Keywords: Autoimmunity; Innate immunity; Lupus; Therapeutics; Vasculitis.

PubMed Disclaimer

Similar articles

See all similar articles

LinkOut - more resources